Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 476–477 (2006)Cite this article

boxed-textRodriguez AE et al. (2006) Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis. The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 47: 1522–1529

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schühlen H et al. (2004) Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 147: 317–322

    Article  Google Scholar 

  2. Gallo R et al. (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99: 2164–2170

    Article  CAS  Google Scholar 

  3. Moses JW et al. (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315–1323

    Article  CAS  Google Scholar 

  4. Hausleiter J et al. (2004) Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 110: 790–795

    Article  CAS  Google Scholar 

  5. Kastrati A et al. (2005) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293: 165–171

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine, interventional cardiologists at the Deutsches Herzzentrum, Technische Universität, Munich, Germany

    Jörg Hausleiter & Adnan Kastrati

  2. Professor of Medicine, interventional cardiologists at the Deutsches Herzzentrum, Technische Universität, Munich, Germany

    Adnan Kastrati

Authors
  1. Jörg Hausleiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adnan Kastrati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adnan Kastrati.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hausleiter, J., Kastrati, A. Is there a role for oral rapamycin in restenosis prevention after bare-metal stent implantation?. Nat Rev Cardiol 3, 476–477 (2006). https://doi.org/10.1038/ncpcardio0633

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0633

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing